Home About us Contact
|
Home About us Contact | ||
|
|
||
Medical Inc. (medical + inc)
Selected AbstractsRadiographic and Computed Tomographic Studies of Calcium Hydroxylapatite for Treatment of HIV,Associated Facial Lipoatrophy and Correction of Nasolabial FoldsDERMATOLOGIC SURGERY, Issue 2008ALASTAIR CARRUTHERS MD OBJECTIVES This study sought to assess the radiographic appearance produced by calcium hydroxylapatite soft tissue filler (CaHA; Radiesse, BioForm Medical Inc.) following augmentation to correct the nasolabial folds or facial wasting associated with human immunodeficiency virus lipoatrophy. METHODS A total of 58 patients, with either lipoatrophy or pronounced nasolabial folds, were treated with CaHA. Radiographic (X-ray) and computed tomographic (CT) imaging studies were conducted pre- and posttreatment in most patients; the images were sent to an independent laboratory to be analyzed by two evaluators who were board-certified radiologists and blinded to study purpose, product, and patient condition. RESULTS While results for X-ray evaluation showed inconsistencies in visualization of CaHA, CT scans showed consistent visualization in nearly all cases in patients who were imaged immediately after treatment. In addition, the results indicated no obscuration of underlying structures by CaHA and no evidence of CaHA migration. CONCLUSIONS Earlier clinical trials established CaHA as a safe and effective soft tissue filler. This CaHA study shows no overt radiographic safety concerns. CaHA is unlikely to be confused with conventional abnormal and adverse radiographic findings. The product is not always visible on X-ray. Although usually visible on CT scans, its appearance is distinct from surrounding bony structures and does not interfere with normal analysis. In addition, the product does not obscure underlying structures on CT scans. [source] Microtensile Bond Strength of Luting Materials to Coronal and Root DentinJOURNAL OF ESTHETIC AND RESTORATIVE DENTISTRY, Issue 3 2005RICARDO WALTER DDS ABSTRACT Purpose:: The purpose of this study was to evaluate the microtensile bond strength (,TBS) of two dual-cured resin cements and a glass ionomer cement to coronal dentin versus root dentin. Materials and Methods: RelyX Unicem (3M ESPE, St. Paul, MN, USA) and Panavia F (Kuraray Medical Inc., Tokyo, Japan) were the resin cements used and FujiCEM (GC Corp., Tokyo, Japan) was the glass ionomer cement used. Once separated, the labial coronal and root surfaces of six bovine incisors were ground with 600-grit SiC papers to expose middle dentin. Then, the dentin surfaces were treated following the manufacturers'instructions and a 1 mm thick layer of each material was applied to the flattened coronal and root surfaces. Each material was cured following the manufacturers'recommendations and a composite buildup was made over the cured luting materials for testing purposes. After 24 hours in water at 37°C, the teeth were sectioned into 1 mm × 1 mm × 6 mm beams and tested for ,TBS. The data were analyzed by one- and two-way analysis of variance and Fisher's Protected Least Squares Differences test (p < .05). Results: The ,TBSs to coronal and root dentin were similar within each cement. Comparing the materials, RelyX Unicem presented the highest ,TBS, followed by Panavia F and FujiCEM, respectively (p < .0001). Conclusions: Although there were differences in ,TBS among the materials tested, no significant differences were found between bond strengths to coronal and root substrates. [source] Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mgALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 5 2001P. O. Katz Background: Single daily doses of proton pump inhibitors, omeprazole and lansoprazole provide effective acid suppression and equal healing and symptom relief in patients with GERD. Despite this, controversy exists as to the efficacy of available proton pump inhibitors in the control of gastric acidity. Aim: To assess the efficacy of omeprazole 20 mg vs. lansoprazole 30 mg and omeprazole 40 mg vs. lansoprazole 30 mg in intragastric pH control. Methods: Study I: 12 Helicobacter pylori -negative volunteers (mean age 33 years) were treated with omeprazole 20 mg and lansoprazole 30 mg in random order before breakfast for 7 days. Study II: 24 subjects (mean age 36 years) were similarly treated with omeprazole 40 mg and lansoprazole 30 mg for 7 days after a baseline pH study. One week washout was allowed between studies. Subjects had the same meal on each study day. On day seven, a 24-h intragastric pH study was performed. The percentage time for which gastric pH > 4 was analysed (Gastrosoft, Synectics Medical Inc.) and expressed as mean ± s.d. Results: (1) Omeprazole 20 mg and lansoprazole 30 mg showed no significant difference in the percentage time for which gastric pH > 4 in the daytime and night-time periods. (2) The percentage time for which pH > 4 with omeprazole 40 mg was significantly greater than lansoprazole 30 mg in both daytime (61 ± 19% vs. 48 ± 14%, P < 0.001), and night-time periods (34 ± 21% vs. 26 ± 14%, P < 0.05). (3) A large inter-subject variation existed in both studies. (4) In 10 subjects who participated in both studies, omeprazole 40 mg showed a significantly higher percentage time for which pH > 4 in the daytime (69 ± 18% vs. 51 ± 15%, P=0.015) than omeprazole 20 mg. Conclusion: These pH data support the therapeutic equivalency of FDA approved doses of omeprazole and lansoprazole. [source] Cryoablation of Accessory Pathways in ChildrenPACING AND CLINICAL ELECTROPHYSIOLOGY, Issue 9 2007VOLKAN TUZCU M.D. Background: Cryoablation is utilized for septal tachycardia substrates due its safety. Considering the recent studies which reveal coronary artery stenosis related to radiofrequency ablation (RFA) in children, cryoablation may offer advantages for nonseptal accessory pathways (APs) as well. The aim of this study was to investigate the efficacy and safety of cryoablation of APs in children. Methods: A total of 39 patients (median age = 9.3 years, range 4.8 to 17.2 years) underwent cryoablation of APs. A three-dimensional, surface electrode-based navigation system (EnSite NavXÔ, St.Jude Medical Inc., St. Paul, MN, USA) is used to decrease the fluoroscopy exposure. Results: A total of 45 APs were identified. Of these APs, 23 were septal (anteroseptal, midseptal, posteroseptal) and 22 were nonseptal. Acute success rate with cryoablation was 73%. RFA was used when cryoablation failed and overall acute success rate was 84%. To assess for the effect of institutional experience, the initial 23 APs were compared to the recent 22 APs and acute success rate revealed significant improvement (57% vs. 91%). Recurrence rate was 24% during a median follow-up of 282 days. Conclusion: Cryoablation of APs is safe and yields to high acute success rates in children. It can potentially be used as the first ablation option for all APs in children. However, recurrence rate is higher compared to the RFA and there is a need for prospective comparative studies. [source] Patient-adjusted intermittent electrostimulation for treating stress and urge urinary incontinenceBJU INTERNATIONAL, Issue 1 2004Israel Nissenkorn OBJECTIVE To assess the safety and efficacy of pelvic floor muscle electrostimulation (ES) in women with stress urinary incontinence (SUI) or mixed UI (MUI, urge and interstitial cystitis), using a new portable electrostimulator (Miniaturo, Biocontrol Medical Inc., Yehud, Israel) which delivers different forms of stimulation for treating these two conditions. PATIENTS AND METHODS For SUI the stimulator is activated on demand only by a sudden increase in intra-abdominal pressure; for frequency and urgency a milder, continuous ES is used. The intensity of ES can be adjusted according to the patient's sensation. Women were enrolled into the study after satisfying inclusion criteria and pad testing; 23 participated in two study groups, i.e. 16 with SUI and seven with MUI (severe frequency, urgency and urge, and mild SUI). The pelvic floor muscles were stimulated through an electrode inserted paraurethrally, positioned similarly in all patients. In patients with SUI and MUI a pressure sensor was also inserted into the rectum, to record intra-abdominal pressure. Stimulation was applied for 1,4 h in patients with SUI and for 6 h in those with MUI. The evaluation was based on urinary symptoms (frequency, urgency, leaking episodes), quality-of-life questionnaires and pad tests at baseline and during stimulation. RESULTS All patients in both groups improved significantly; of the 16 patients with SUI, nine were completely dry during ES, and the remaining seven had a reduced mean pad weight, from 23 to 6 g (74%). There was no significant reduction in pad weight after sham ES (17 g before vs 24.2 g after). In four patients with SUI who continued ES for 4 h the mean cumulative stimulation time (calculated from the stimulator memory) was 3 min (1.3% of 4 h). In the MUI group there were no leakage episodes during ES and significant reductions in voiding variables (Student's t -test) in all. The mean (Sd) voiding frequency, urinary urgency and leaking episodes decreased from 8.1 (4.2) to 1.9 (1.5), 6.4 (2.3) to 0.7 (1.3) and 2.1 (0.7) to 0.7 (0.5) (all P < 0.001), respectively. CONCLUSIONS The concept of this ES system for treating UI is promising; this study supports the efficacy of this form of ES but no conclusions about clinical efficacy are possible at this stage, and thus a trial to evaluate the safety and efficacy of this implantable device is ongoing. [source] | ||||||||||